Galantamine HBr .
ApprovedSmall molecule
Galantamine HBr . is one of 11 small molecule programs targeting Lewy body dementia. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Lewy Body Dementia
#DrugCompanyPhaseTrials
1Exelon
NovartisApproved
Bosulif
PPrism Pharmaceuticals
Approved
Reminyl
WWim Janssens
Approved
Tasigna
AAzurity Pharmaceuticals
Approved
ACP-204
AACADIA Pharmaceuticals Inc.
Phase 3
Galantamine HBr .
VVirginia Commonwealth University
Approved
Datscan
NNavidea Biopharmaceuticals
Phase 3
Ambroxol Hydrochloride
Boehringer IngelheimPhase 2
LY3154207
Eli LillyPhase 2
Nelotanserin
AAxovant Sciences Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Galantamine HBr .. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- VVirginia Commonwealth University